-
Start Preamble
Start Printed Page 5700
AGENCY:
Food and Drug Administration, HHS.
ACTION:
Final rule.
SUMMARY:
The Food and Drug Administration (FDA) is amending the animal drug regulations to reflect a change of sponsor for an abbreviated new animal drug application (ANADA) for chlortetracycline soluble powder from Teva Animal Health, Inc., to Quo Vademus, LLC.
DATES:
This rule is effective February 6, 2012.
Start Further InfoFOR FURTHER INFORMATION CONTACT:
Steven D. Vaughn, Center for Veterinary Medicine (HFV-100), Food and Drug Administration, 7520 Standish Pl., Rockville, MD 20855, (240) 276-8300, email: steven.vaughn@fda.hhs.gov.
End Further Info End Preamble Start Supplemental InformationSUPPLEMENTARY INFORMATION:
Teva Animal Health, Inc., 3915 South 48th Street Ter., St. Joseph, MO 64503, has informed FDA that it has transferred ownership of, and all rights and interest in, ANADA 200-236 for Chlortetracycline HCL Soluble Powder to Quo Vademus, LLC, 277 Faison McGowan Rd., Kenansville, NC 28349. Accordingly, the Agency is amending the regulations in 21 CFR 520.441 to reflect the transfer of ownership.
Quo Vademus, LLC, is not currently listed in the animal drug regulations as a sponsor of an approved application. Accordingly, 21 CFR 510.600 is being amended to add entries for this sponsor.
This rule does not meet the definition of “rule” in 5 U.S.C. 804(3)(A) because it is a rule of “particular applicability.” Therefore, it is not subject to the congressional review requirements in 5 U.S.C. 801-808.
Start List of SubjectsList of Subjects
21 CFR Part 510
- Administrative practice and procedure
- Animal drugs
- Labeling
- Reporting and recordkeeping requirements
21 CFR Part 520
- Animal drugs
Therefore, under the Federal Food, Drug, and Cosmetic Act and under authority delegated to the Commissioner of Food and Drugs and redelegated to the Center for Veterinary Medicine, 21 CFR parts 510 and 520 are amended as follows:
Start PartPART 510—NEW ANIMAL DRUGS
End Part Start Amendment Part1. The authority citation for 21 CFR part 510 continues to read as follows:
End Amendment Part Start Amendment Part2. In § 510.600, in the table in paragraph (c)(1), alphabetically add a new entry for “Quo Vademus, LLC”; and in the table in paragraph (c)(2), in numerical sequence add a new entry for “076475” to read as follows:
End Amendment PartNames, addresses, and drug labeler codes of sponsors of approved applications.* * * * *(c) * * *
(1) * * *
Firm name and address Drug labeler code * * * * * Quo Vademus, LLC, 277 Faison McGowan Rd., Kenansville, NC 28349 076475 * * * * * (2) * * *
Drug labeler code Firm name and address * * * * * 076475 Quo Vademus, LLC, 277 Faison McGowan Rd., Kenansville, NC 28349 * * * * * PART 520—ORAL DOSAGE FORM NEW ANIMAL DRUGS
End Part Start Amendment Part3. The authority citation for 21 CFR part 520 continues to read as follows:
End Amendment Part[Amended]4. In paragraph (b)(4) of § 520.441, remove “059130” and in its place add “076475”.
End Amendment Part Start SignatureDated: February 1, 2012.
William T. Flynn,
Acting Director, Center for Veterinary Medicine.
[FR Doc. 2012-2633 Filed 2-3-12; 8:45 am]
BILLING CODE 4160-01-P
Document Information
- Effective Date:
- 2/6/2012
- Published:
- 02/06/2012
- Department:
- Food and Drug Administration
- Entry Type:
- Rule
- Action:
- Final rule.
- Document Number:
- 2012-2633
- Dates:
- This rule is effective February 6, 2012.
- Pages:
- 5700-5700 (1 pages)
- Docket Numbers:
- Docket No. FDA-2011-N-0003
- Topics:
- Administrative practice and procedure, Animal drugs, Labeling, Reporting and recordkeeping requirements
- PDF File:
- 2012-2633.pdf
- Supporting Documents:
- » Freedom of Information Summary NADA 141-324 Phenylpropanolamine
- » Freedom of Information Summary NADA 141-331 Pergolide
- » Freedom of Information Summary NADA 141-333 - Milbemycin Oxime, Lufenuron, and Praziquantel
- » Freedom of Information Summary NADA 095-735 - Monensin
- » Freedom of Information Summary NADA 141-207 - Danofloxacin
- » Freedom of Information Summary NADA 141-322 - Gonadotropin Releasing Factor Analog-Diphtheria Toxoid Conjugate
- » Freedom of Information Summary ANDA 200-494 - Gentamicin Sulfate
- » reedom of Information Summary NADA 141-203 Deracoxib
- » Gentamicin Topical Spray (gentamicin sulfate, betamethasone valerate- ANADA 200-416; Freedom of Information Summary
- » Freedom of Information Summary ANDA 200-318 Bimectin Pour-On (Ivermectin)
- CFR: (2)
- 21 CFR 510.600
- 21 CFR 520.441